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Oncogenic K-RAS has been difﬁcult to target and currently there is no K-RAS-based targeted therapy available for patients
suffering from K-RAS-driven lung adenocarcinoma (AC). Alternatively, targeting K-RAS-downstream effectors, K-RAS-cooperating
signaling pathways or cancer hallmarks, such as tumor-promoting inﬂammation, has been shown to be a promising therapeutic
strategy. Since the JAK–STAT pathway is considered to be a central player in inﬂammation-mediated tumorigenesis, we
investigated here the implication of JAK–STAT signaling and the therapeutic potential of JAK1/2 inhibition in K-RAS-driven lung
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AC. Our data showed that JAK1 and JAK2 are activated in human lung AC and that increased activation of JAK–STAT signaling
correlated with disease progression and K-RAS activity in human lung AC. Accordingly, administration of the JAK1/2 selective
tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in
immunodeﬁcient and immunocompetent mouse models of K-RAS-driven lung AC. Notably, JAK1/2 inhibition led to the
establishment of an antitumorigenic tumor microenvironment, characterized by decreased levels of tumor-promoting
chemokines and cytokines and reduced numbers of inﬁltrating myeloid derived suppressor cells, thereby impairing tumor
growth. Taken together, we identiﬁed JAK1/2 inhibition as promising therapy for K-RAS-driven lung AC.
What’s new?
A drug that inhibits the JAK–STAT pathway may score a hit against K-RAS driven lung cancer. Here, the authors Investigated
the JAK STAT pathway as a possible target in lung adenocarcinoma because of its role in inﬂammation-mediated tumorigenesis.
First, they showed that JAK1 and JAK2 are both activated in lung adenocarcinoma patients with oncogenic mutations in K-RAS.
Next, they treated the tumors with ruxolitinib, which inhibits JAK1/2. The drug successfully slowed tumor proliferation and
progression in immunocompetent mouse models. Furthermore, treatment with ruxolitinib reduced the tumor-promoting factors
present in the microenvironment.
Introduction
Lung cancer is still the leading cause of cancer-related deaths
worldwide in both men and women.1 Histologically, lung cancer
can be subdivided into small cell lung cancer and non-small cell
lung cancer, with lung adenocarcinoma (AC) being the most
abundant among the non-small cell lung cancer subtype.2
Roughly 50% of lung ACs harbor oncogenic mutations in the V-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-RAS) or
epidermal growth factor receptor (EGFR).3,4 While EGFR tyro-
sine kinase inhibitors, such as erlotinib, geﬁtinib or afatinib, are
part of the clinical routine to treat EGFR-mutated lung AC
patients,5 the development of K-RAS inhibitors has been less
successful so far, with no K-RAS-based targeted therapy being
clinically approved.6 Hence, targeting alternative tumor drivers
fueling K-RAS-mediated lung tumorigenesis such as tumor-
promoting inﬂammation and K-RAS downstream effector path-
ways are considered to be a promising treatment strategy.6,7
Given the pivotal role of Janus kinase (JAK) activation in
tumor-promoting inﬂammation and its oncogenic functions,
JAKs represent attractive therapeutic targets in tumorigenesis.8
The JAK family is composed of four members (JAK1, JAK2, JAK3
and tyrosine kinase 2) and couples extracellular stimuli with gene
transcription. Upon cytokine binding to their cognate receptors,
JAKs become activated and phosphorylate downstream signal
transducer and activator of transcription (STAT) molecules, ulti-
mately leading to nuclear translocation and transcription of vari-
ous target genes involved in cell cycle regulation, angiogenesis,
apoptosis, tumor invasion and metastasis.9 JAK signaling either
promotes or suppresses tumorigenesis in a tumor cell intrinsic
manner. Indeed, K-RAS-mutated lung AC cells secrete pro-
inﬂammatory cytokines including interleukin (IL)-6 that activate
JAK1 and JAK2 via glycoprotein 130 in an autocrine loop, thereby
promoting tumor cell survival.7,10,11 On the other hand, genetic
deletion of STAT3, a key signaling mediator of JAK1/2, enhances
K-RAS-driven lung tumorigenesis, and activation of the inter-
feron/JAK/STAT axis induces cell apoptosis and suppresses
tumorigenesis in various experimental tumormodels.12–16
In addition to these tumor-cell intrinsic effects, JAK signaling
is also substantially involved in shaping the tumor microenviron-
ment (TME) by modulating T, natural killer (NK) and dendritic
cell functions.17 As in tumor cells, JAK activation in the TME and
its role in tumorigenesis is controversially discussed. While
JAK1/2 inhibition impairs NK-cell function and NK mediated
antitumor immunity and hence indirectly facilitates tumor meta-
static spread,18 targeting the JAK–STAT axis has also been
proposed as a potential effective strategy to reduce levels of tumor-
promoting immunosuppressive myeloid derived suppressor cells
(MDSCs), thereby counteracting malignant progression.19 Fur-
thermore, IL6/JAK/STAT3, as well as interferon-γ/JAK/STAT1
signaling pathways have also been described to induce pro-
grammed cell death 1 and or programmed cell death 1 ligand
1 (PD-L1) expression and, therefore, to promote tumor immune
escape.20,21 Taken together, these reports indicate that JAKs may
have opposite functions in tumorigenesis depending on the cellular
context.
Clinical trials investigating JAK inhibition in particular for
EGFR-mutated lung cancers are ongoing. These studies combine
the JAK inhibitors ruxolitinib, itacitinib and AZD4205 with the
EGFR tyrosine kinase inhibitors erlotinib (NCT02155465), afatinib
(NCT02145637) and osimertinib (NCT02917993, NCT03450330).
By contrast, JAK targeting in K-RAS-mutated lung ACs has not
been thoroughly investigated so far. Notably, a recent clinical
trial showed positive results when combining ruxolitinib and che-
motherapy in non-small cell lung cancer patients, but the K-RAS
mutation status is not available (NCT02119650). Thus, to comple-
ment these clinical studies, we addressed the role of JAK1/2 in
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K-RAS-driven lung AC pathogenesis. By using human tumor
samples and experimental mouse models, we show that JAK1/2 are
activated in K-RAS-driven lung AC and promote tumor growth
and progression by establishing a protumorigenic TME. Impor-
tantly, pharmacological inhibition of JAK1/2 with the tyrosine
kinase inhibitor ruxolitinib reverts the protumorigenic TME and
impairs tumorigenesis.
Materials and Methods
Human data
For gene expression analysis, we took advantage of the publicly
available Illumina microarray data set, which contains biopsies of
K-RAS-mutated lung AC tissue and adjacent healthy tissue
(GSE75037).22 To determine JAK1 and JAK2 mRNA expression
levels, we used probes as depicted in Table S1. As a second cohort,
we used gene expression data from K-RAS-mutated lung AC
patients included in the Cancer Genome Atlas (n = 154).23
Gene set enrichment analysis (GSEA) was performed accor-
ding to the provider’s protocol and permutations were set to
1,000.24 Gene sets were downloaded from the Molecular Signa-
ture Database (http://software.broadinstitute.org/gsea/msigdb/
index.jsp). To determine the prognostic value of chemo/cytokine
related genes upon ruxolitinib treatment for human lung ACs
pathogenesis, we used the KM-Plotter online tool.25 In addition,
gene expression data of K-RAS-mutated lung AC patients with
available survival data included in the Cancer Genome Atlas were
analyzed ( n = 150).23 We have run the analysis by evaluating all
possible cutoff values and the best performing value was used as
the cutoff in the ﬁnal analysis. False discovery rate was computed
to correct for multiple testing, and only results having a false dis-
covery rate below 1% was accepted as statistically signiﬁcant.
Analysis was performed using the mean expression of the genes
included in the multigene signature, and all utilized Probe-IDs
are shown in Table S2.
For immunohistochemical analysis, we generated tissue
microarrays from two independent lung AC patient cohorts.
Cohort A includes biopsies from lung AC patients where
information about the mutational K-RAS status was not avail-
able (pJAK1 n = 303, pJAK2 n = 318). Cohort B consists of
biopsies of lung AC patients positive for K-RAS mutation
(pJAK1 n = 26, pJAK2 n = 24). Analysis was done with prior
approval by the institutional ethical committee. For detection
of JAK1 or JAK2 tyrosine phosphorylation the tissue micro-
arrays were stained with a pJAK1 (1:200, Y1022, #PA537617,
Thermo Fisher Scientiﬁc, Waltham, MA) and a pJAK2 (1:200,
Y1007 and Y1008, #32101, Abcam, Cambridge, UK) antibody.
Histoscores were determined according to staining intensities
and percentage of positive tumor cells by a board-certiﬁed
pathologist (H.P.).26
Cell lines
The human K-RAS-mutated lung AC cell lines A549 and A427
were grown in RPMI medium (Gibco, Grand Island, NY) sup-
plemented with 10% FBS, 2 mM glutamine (Gibco), penicillin
(50 U/ml, Gibco) and streptomycin (50 μg/ml, Gibco). A549 and
A427 cell lines were obtained from American Type Culture Col-
lection, and cells were proﬁled for authentication (Euroﬁns Geno-
mics, Luxembourg). Cells were tested to be free of mycoplasma
contaminations twice a year. For experiments, cells were harvested
at ~70% conﬂuency, and the number of viable cells was deter-
mined using a CASY counter (Roche, Basel, Switzerland).
Animal husbandry and experiments
For subcutaneous xenograft experiments using the K-RAS-
mutated human lung AC cell lines A549 and A427, 1 × 106
cells were mixed 1:2 with Matrigel (Corning, Corning, NY)
and injected into the right and left ﬂank of immunodeﬁcient
NOD scid gamma mice older than 6 weeks of age. Tumor vol-
ume was measured using a caliper and tumor volume was cal-
culated using the formula [(length × width2) × 0.52] as
previously established in our laboratory.27
K-rasLSL-G12D (K) mice as well as K-rasLSL-G12D:p53ﬂ/ﬂ
(KP) mice, both bred on a C57Bl/6 background, served as geneti-
cally engineered mouse models for autochthonous lung AC.28
Genotyping of the transgenes was performed using primers
depicted in Table S3. Induction of lung tumors in these geneti-
cally engineered mouse models was achieved through intranasal
inhalation of a Cre-recombinase expressing adenovirus (Ad.Cre)
in 8–12 week old mice using 2.5 × 107 plaque-forming units.
Inhalation of K and KP mice with Ad.Cre triggers K-rasG12D acti-
vation in lung epithelial cells resulting in formation of p53
expressing (K) or deﬁcient (KP) lung ACs. Ad.Cre was purchased
from the Viral Vector Core (University of Iowa). For treatment of
mice with the JAK1/2 inhibitor ruxolitinib (LC Labs, Woburn,
MA), the inhibitor was suspended in 0.5% (w/v) methylcellulose
solution. Mice were treated via oral gavage with vehicle (ctrl,
0.5% Methylcellulose) or ruxolitinib (Ruxo) at 90 mg/kg twice a
day (BID), 7 days per week for the indicated experimental time
period. Treatment of mice was paused if any signs of distress
occurred.18 All experimental protocols as well as animal mainte-
nance and breeding described above, followed ethical guidelines
and were approved by the Austrian Federal Ministry of Science,
Research and Economy.
Histology
At the experimental endpoint, subcutaneously engrafted tumor
tissue or lung tissue was retrieved and ﬁxed in 2% buffered
formaldehyde at 4C for 24 hr and embedded in parafﬁn after
dehydration. Five micron sections were used for analysis. To
determine tumor area, lung sections were stained with hematoxy-
lin and eosin and subsequently scanned using TissueFaxs
(TissueGnostics, Vienna, Austria) software. Tumor area and
number were quantiﬁed using HistoQuest (TissueGnostics) soft-
ware. Tumor grades were determined by a board-certiﬁed pathol-
ogist Katalin Dezso (K.D.) according to DuPage et al.28 For
immunohistochemistry, standard protocols were applied, using
antibodies against pSTAT3 (1:200,Y705, #9145, Cell Signaling,
Danvers, MA), KI67 (1:400, Cell Signaling #12202 or 1:200,
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#14-5698-82, eBioscience, San Diego, CA), cleaved caspase-3
(1:200, Cell Signaling #9661), cluster of differentiation 31 (1:400,
Cell Signaling #77699), PD-L1 (1:200, Cell signaling #64988). For
analysis of stained immunohistochemistry slides HistoQuest
(TissueGnostics) software was used.
RNA-sequencing (RNA-seq) analysis of total lungs and Gene
Expression Omnibus data set analysis
For RNA-seq analysis, K mice were treated 8 weeks post inhala-
tion with Ad.Cre for four consecutive days with vehicle (0.5%
Methylcellulose) or ruxolitinib (90 mg/kg BID). Additionally
tumor harboring lungs from KP mice and lungs from wild-type
(WT) mice were included in the analysis. At the experimental
endpoint, lungs were harvested and RNA was isolated using the
RNeasy Kit (Qiagen, Venlo, Netherlands) following on column
DNA digestion using RNase-Free DNase (Qiagen). Library prep-
aration and sequencing was carried out by the Core facility Geno-
mics, Medical University of Vienna, Vienna, Austria. Brieﬂy,
sequencing libraries were prepared using the NEBNext® Ultra™
II RNA Library Prep Kit (NEB, Ipswich, MA) according tomanu-
facturer’s instructions and sequenced on a Illumina NextSeq500
platform in a 75 bp single-read mode. RNA-Seq data were
mapped to the Mus musculus/mmc10 assembly of the murine
genome using the STAR Aligner.29 Differential gene expression
was analyzed using DESeq2.30
For GSEA, gene sets were downloaded from the Molecular
Signature Database (http://software.broadinstitute.org/gsea/
msigdb/index.jsp). For gene ontology (GO)-molecular func-
tion analysis, the Enrichr web tool was used (http://amp.
pharm.mssm.edu/Enrichr/enrich). The top 350 downregulated
genes (based on log2 fold changes) in the ruxolitinib treated
group were subjected to pathway analysis with Enrichr.31 To
investigate the implications of ruxolitinib downregulated
chemo/cytokine related genes for K-RAS-driven lung tumori-
genesis, we retrieved all genes within the chemo/cytokine
related GO gene sets GO0042379, GO0008009, GO0045236,
GO0048020 and GO0005125. Data were analyzed using the
web-based online tool InteractiVenn,32 and for hierarchical
clustering and heatmap illustration, we used the heatmapper.
ca web tool.33 In order to check for the activation status of
the JAK–STAT pathway and the expression of
chemo/cytokine related genes in primary K-rasG12D-mutated
lung alveolar type II (K) cells, we analyzed the publically
available GSE113146 data set.27
RNA extraction and real-time quantitative polymerase chain
reaction
RNA isolation from the lungs was performed using TRIzol™
Reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. Complementary DNA was transcribed using the
RevertAid HMinus Reverse Transcriptase (Fermentas, Waltham,
MA) kit. For detection of the transcript, the iTaq Universal SYBR
Green reagent (Biorad, Hercules, CA) and a Biorad CFX Connect
Real Time polymerase chain reaction system were utilized, using
speciﬁc primers depicted in Table S4. For determination of rela-
tive gene expression ratios, the Pfafﬂmethod was applied. Calcu-
lation of bestkeeper values was performed using actin beta
(ACTB), 28S and TATA-box binding protein (TBP) as house-
keeping genes.34
Flow cytometric analysis of total lungs
At the experimental endpoint, K-RAS-mutated tumor harboring
lungs were harvested, and the lung tissue was mechanically and
enzymatically disrupted for cell isolation. Brieﬂy, lungs were put
into isolation medium (RPMI with 5% FBS) and minced with
scissors. Minced pieces were then transferred into a falcon tube
containing isolation medium supplemented with DNase I
(50 U/ml, Sigma, St.Louis, MO) and Collagenase I (Gibco,
150 U/ml), and incubated for 1 hr at 37C. Subsequently, the cell
suspension was ﬁltered through 70 and 40 μm cell strainers. For
subsequent ﬂow cytometric analysis, cells were stained with the
antibodies indicated in Table S5 using a standard protocol. For
identiﬁcation of Th17 and regulatory T cells, the mouse Th17/
Treg phenotyping kit (#560767, BD Pharmingen, Franklin Lakes,
NJ) was used. All cells are CD45+. Stained samples weremeasured
using the BD FACSCanto™ II system. For data analysis, the
FlowJo software (TreeStar, Inc., Ashland, OR) was used.
Statistical analysis
All values are presented as mean  standard error of mean. For
single outlier detection the Grubbs-test was used, multiple out-
liers were deﬁned when values were lower than Q1–1.5 × inter-
quartile range or greater than Q3 + 1.5 × interquartile range
(difference between the third quartile [Q3] and ﬁrst quartile
[Q1]). Subsequent statistical analyses were either performed uti-
lizing Student’s t-test or Mann–Whitney U-test calculated by
GraphPad Prism 5.0 software. For multiple group comparison,
one-way analysis of variance (ANOVA) in combination with
Tukey’s multiple comparison test was used. For GO-molecular
function analysis, the results were ranked according to the
adjusted p-value. For Kaplan–Meier analysis, the Log-rank test
was used and false discovery rate was computed to combat for
multiple hypothesis testing. For all graphs: *p < 0.05; **p < 0.01;
***p < 0.001.
Data availability
All materials will be made available to the scientiﬁc commu-
nity. RNAseq data are available within the sequence read
archive (SRA) with the accession number PRJNA518030.
Results
JAK signaling is activated in human K-RAS-mutated lung AC
during tumor progression
To investigate the implication of JAK1 and JAK2 for the patho-
genesis of human K-RAS-mutated lung AC, we took advantage of
the publicly available mRNA expression data set GSE75037.22
Comparison of JAK1 and JAK2 mRNA expression levels of stage
I classiﬁed K-RAS-mutated lung AC patients versus those with
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more advanced disease revealed increased JAK1/2 expression
levels in the latter group, which reached signiﬁcance for JAK1
(Fig. 1a). In line with these data, we found activation of the JAK–
STAT pathway in patients with more advanced lung AC (i.e., in
stage II disease), as determined by GSEA (Fig. 1b).24 Next, we
conﬁrmed these data in K-RASmutated lung AC patients from a
different cohort published by the Cancer Genome Atlas.23
Indeed, we found a signiﬁcant correlation of JAK1 and JAK2
mRNA expression levels with enrichment of K-RAS signaling in
lung AC patients (Figs. 1c and 1d). Moreover, we noticed a signif-
icant increase of JAK1 and JAK2mRNA expression in tumors of
late stage patients with oncogenic K-RAS mutations compared to
patients harboring K-RAS WT tumors, which was not observed
in early stage patients (Figs. S1a and S1b).
However, using mRNA expression data of bulk tumor tissue
does not allow distinguishing between tumor and stromal cells.
Hence, we performed immunohistochemistry for activated JAK1
and JAK2 in biopsies of lung AC patients from two independent
cohorts (cohorts A&B, consisting of unselected and K-RAS
mutated samples, respectively). Indeed, JAK1 and JAK2 were
activated/phosphorylated in tumor cells of lung AC patients as
determined by a pathologist (H.P.). In the stroma, a positive reac-
tion for JAK1 and JAK2 was mainly found in lymphocytes
(Figs. 1e and 1f ). Taken together, these data indicated that JAK
signaling is active in humanK-RAS-driven lung AC.
JAK inhibition impairs human K-RAS-mutated lung AC cell
growth in vivo
Next, we assessed the potential beneﬁts of pharmacological JAK1/2
inhibition in K-RAS-driven lung AC using the JAK1/2 selective
tyrosine kinase inhibitor ruxolitinib. We performed subcutaneous
engraftments of human lung AC cell lines harboring oncogenic K-
RAS mutations into immunodeﬁcient NOD scid gamma
mice. Intriguingly, ruxolitinib treatment signiﬁcantly attenuated
growth of the human K-RASG12S-mutated lung AC cell line A549
(Figs. 2a–2c), and impaired growth of A427 (K-RASG12D)
transplanted cells (Figs. S2a and S2b). Immunohistochemistry
analysis of proliferation and apoptosis markers within tumors
Figure 1. JAK-mediated signaling is activated in progressing K-RAS-mutated human lung AC. (a) Graph showing relative JAK1 and JAK2 mRNA
expression levels in human K-RAS-mutated lung AC tissue of stage I (n = 19) versus stage II or higher (≥II, n = 8). Data represent mean  SEM,
A.U (arbitrary units), Student’s t-test, *p < 0.05. (b) GSEA for Kyoto encyclopedia of genes and genomes-JAK–STAT pathway signature geneset
comparing human K-RAS-mutated tumors of stage I versus stage II, using tumor versus healthy parenchyma mRNA expression ratios. Data in (a)
and (b) were retrieved from the Gene Expression Omnibus (GSE75037). (c) GSEA using gene expression data of the Cancer Genome Atlas-LUAD
cohort and HALLMARK_KRAS_SIGNALING_UP geneset, stratifying patients according to JAK1 and (d) JAK2 expression levels (n = 154). (e)
Representative pictures of lung AC biopsies of patients included in cohort A (unknown K-RAS mutation status; pJAK1 n = 303, pJAK2 n = 318)
and (f ) cohort B (K-RAS mutated; pJAK1 n = 26, pJAK2 n = 24) with negative and positive staining reactions for pJAK1 and pJAK2 in tumor cells.
Graphs represent percentage of positive and negative cases within the respective cohort. Staining intensities and percentage of positive tumor
cells were determined by a board-certiﬁed pathologist (H.P.). [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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revealed that JAK inhibition signiﬁcantly reduced proliferation and
slightly increased apoptosis of transplanted lung AC cells (Figs. 2d
and 2e). JAK1/2 inhibition in tumor cells of ruxolitinib treated
mice was efﬁcient, since activation of the downstream effector
STAT3 was almost absent after tyrosine kinase inhibitor treatment
(Figs. 2d and 2e). Accordingly, ruxolitinib treatment impaired a
well-described autocrine oncogenic activation loop in this model.10
Indeed, tumor cell-derived expression of pro-inﬂammatory cyto-
kines IL-6 and IL-1β was signiﬁcantly decreased in the ruxolitinib
treated group, as veriﬁed by quantitative real-time PCR using
primers speciﬁc for the human transcripts of these cytokines
(Fig. 2f). Notably, the ruxolitinib dose used in our experiments was
generally well tolerated by the experimental mice, and we did not
observe any signiﬁcant body weight loss in the treated groups
(Fig. S2c). Since abrogation of JAK signaling may also impair
angiogenesis,35 we checked expression of the angiogenic markers
Vegfα and Hif1α and evaluated numbers of cluster of differentia-
tion 31+ vessels, but we did not observe changes upon ruxolitinib
treatment (Figs. S2d and S2e).
Ruxolitinib attenuates tumorigenesis of autochthonous K-
RAS-driven lung AC
Although cell-line-derived xenograft models have the advantage
to study tumors of human origin, a major drawback of these
models is the absence of a functional immune system.36 However,
this is a critical factor in our study, since ruxolitinib was reported
Figure 2. JAK inhibition impairs growth of human K-RAS-mutated lung AC cells in vivo. (a) Mean volumes of xenografted A549 derived tumors
in mice treated with vehicle control (ctrl) or ruxolitinib (Ruxo) at 90 mg/kg body weight, seven times per week, BID, and (b) the endpoint
tumor weight. (c) Representative pictures of A549 tumor-derived xenografts after ctrl or Ruxo treatment. (d) Representative pictures of
immunohistochemical stainings for KI67, cleaved caspase 3 (CC3) and p-STAT3 staining of A549 cell line derived xenograft tumors upon ctrl
and Ruxo treatment (scale bar: 100 μm), and (e) quantitation of positive cells for respective stainings. (f ) Relative mRNA expression of human
transcript variants of indicated genes normalized to human housekeeping genes (28S, TBP, ACTB) in A549 derived xenografted tumors. (d–f )
n = ≥ 5 tumors per group. For all graphs Student’s t-test: *p < 0.05, **p < 0.01, ***p < 0.001. For all graphs data presented as means  SEM.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Figure 3. Ruxolitinib attenuates tumorigenesis of autochthonous K-RAS-driven lung AC. (a) Left panel: representative pictures of hematoxylin
and eosin stained lung sections of vehicle control (ctrl) or ruxolitinib (Ruxo) treated K-rasG12D (K) mice (n = 7 per group) and K-rasG12D:p53ﬂ/ﬂ
(KP) mice (n = 8 per group). Treatment was started 1 week post tumor initiation, and continued for 10 weeks, with ruxolitinib being
administered at 90 mg/kg body weight, seven times per week, BID (scale bars: 400 μm). Right panel: quantitation of hematoxylin and eosin
stained lung sections from K mice (upper) and KP-mice (lower) treated with ctrl or Ruxo started 1 week post tumor initiation and continued
for 10 weeks. (b) Graph depicts tumor numbers per section stratiﬁed by tumor grades. Per mouse, one section was analyzed (n = 8 mice per
group). (c) Left panel: representative pictures of immunohistochemical stainings for KI67 positive cells of lungs stemming from ctrl and Ruxo
treated K and KP mice. Right panel: quantitation of indicated stainings. (d) Left panel: cleaved caspase-3 positive cells of lungs of ctrl and
Ruxo treated K and KP mice. Right panel: quantitation of indicated stainings (scale bars: 50 μm). (c, d) Mann–Whitney U-test, *p < 0.05,
**p < 0.01, ***p < 0.001. Others: Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. For all graphs data presented as means  SEM. [Color
ﬁgure can be viewed at wileyonlinelibrary.com]
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to promote immunosuppression and could thereby eventually
enhance tumor progression.18 Thus, we addressed the effects of
JAK1/2 inhibition in fully immunocompetent mouse models of
autochthonous K-RAS-driven lung AC. Therefore, we took
advantage of the K-rasLSL-G12D (K) and K-rasLSL-G12D:p53ﬂ/ﬂ
(KP) mice. Inhalation of K and KP mice with a Cre-recombinase
expressing adenovirus (Ad.Cre) triggers K-rasG12D activation in
lung epithelial cells, resulting in formation of p53 expressing
(K) or deﬁcient (KP) lung ACs. Of note, KP mice develop lung
ACs showing features of advanced grade tumors.28,37 First, we
validated the mouse models by isolating primary lung alveolar
type II cells derived from K mice and inducing the expression of
oncogenic KRAS in vitro. Intriguingly, global gene expression
analysis revealed that K-rasG12D expression resulted in activation
of the JAK–STAT pathway (Figs. S3a and S3b).27 Encouraged by
these data, we treated K and KP mice 1 week after tumor
Figure 4. Legend on next page.
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induction with ruxolitinib or vehicle control for a period of
10 weeks, euthanized them and analyzed their lungs. We noticed
a signiﬁcant decrease in tumor burden in ruxolitinib treated mice
compared to vehicle-treated controlmice, as indicated by reduced
lung weight to body weight and tumor to lung area ratios, con-
comitant with reduced tumor numbers (Fig. 3a). Of note, sex dif-
ferences in treatment response were not observed in our mouse
models (Fig. S4a). Furthermore, grading of tumors by a patholo-
gist (K.D.) revealed that ruxolitinib blocked the progression of K-
RAS-driven lung tumors. Indeed, ruxolitinib treatment resulted
in a signiﬁcant reduction of high grade tumors compared to vehi-
cle control, which reached signiﬁcance for grade III tumors
(Fig. 3b and Fig. S4b). No differences in body weights were
observed between control and treatment groups (Figs. S4c and
S4d). Similar to the engrafted human lung AC cells, ruxolitinib
signiﬁcantly attenuated tumor cell proliferation in these mice
(Fig. 3c). Intriguingly, we observed a higher rate of tumor cell
apoptosis in the vehicle treated compared to ruxolitinib group in
both K and KP mouse models (Fig. 3d). Importantly, there were
no differences in the expression levels of the angiogenic factors
Hif1α and Vegfα between control and ruxolitinib treatment
groups (Figs. S4e and S4f ), suggesting that impairment of tumor
cell proliferation is responsible for the reduced tumor burden
upon ruxolitinib treatment in these models.
JAK inhibition impairs progression of established K-RAS-
mutated lung AC and modulates the TME
Having demonstrated that ruxolitinib effectively reduces tumori-
genesis when administered at early stages of tumor formation, we
questioned whether ruxolitinib prevents progression of already
established K-RAS-driven lung AC in a therapeutic setting. There-
fore, we treated K mice with ruxolitinib starting 8 weeks post Ad.
Cre inhalation for ﬁve consecutive weeks. In this model, we
observed a reduction in lung to body weight ratios and total tumor
area per lung section after ruxolitinib treatment as compared
to vehicle control treatment, while tumor numbers remained
unaltered (Fig. 4a). Notably, analysis of tumor to lung area ratios
did not show differences between the treatment groups, most
likely because total lung areas were smaller upon ruxolitinib treat-
ment (Figs. S5a–S5c). Strikingly, grading of tumors revealed a
reduction of high-grade tumors, namely tumors of grades II and
III (Fig. 4b). In addition, ruxolitinib treatment of mice with
established tumors also triggered signiﬁcant reduction in tumor
cell proliferation and increased apoptosis (Fig. 4c). Similar to the
previous models, differences in mRNA expression levels of angio-
genic markers Hif1α and Vegfα were not observed and body
weights showed no signiﬁcant differences between control and
ruxolitinib treatment groups (Figs. S5d and S5e). These data sug-
gests that ruxolitinib impairs the progression of established K-
RAS-driven lung AC. Since JAK signaling plays a crucial role in
regulating the immune system, we analyzed if JAK1/2 inhibition
affected the composition of the TME by performing ﬂow
cytometric analysis of lung tumors.17 Indeed, the abundance of
tumor promoting granulocytic CD45+CD11b+LY6G+ and mono-
cytic CD45+CD11b+LY6C+ MDSC38 was signiﬁcantly reduced in
the lungs of tumor-bearing, ruxolitinib-treated mice. Further-
more, the number of tumor promoting CD45+CD11b+CD206+
M2 macrophages was lowered upon JAK1/2 inhibition (Fig. 4d).
With respect to the lymphoid lineage, our analysis revealed signiﬁ-
cantly diminished NK cell numbers upon ruxolitinib administra-
tion in tumor bearing lungs of these mice (Fig. 4d). These data are
in line with a previous report using a preclinical breast cancer
model.18 In addition, we observed a slight reduction in inﬁltrating
CD8+ and CD4+ T cells upon ruxolitinib treatment, but an
increase in CD4+IL17A+ Th17 cells as well as CD4+Foxp3+ regula-
tory T cells (Fig. 4d). Moreover, JAK inhibition lead to a signiﬁ-
cant impairment of NK and CD8+ T cell activation, but on the
other hand also abrogated interferon-γ-mediated STAT1 signal-
ing and hence reduced PD-L1 expression (Figs. 4e–4g). In sum-
mary, these data indicated that ruxolitinib altered the myeloid
compartment of the TME toward an antitumorigenic state, which
out-competed the suppressing effects of ruxolitinib on inﬁltrating
cytotoxic NK and CD8+T cells.
JAK inhibition abrogates expression of oncogenic
chemokines and cytokines
Next, we thought to unravel the transcriptional changes, leading
to the establishment of an antitumorigenic TME upon ruxolitinib
treatment. Therefore, we performed RNA-seq analysis of short-
term (4 days) treated tumor-bearing lungs from K mice with
Figure 4. JAK inhibition impairs progression of established K-RAS-mutated lung AC and alters TME. (a) Left panel: representative pictures of
hematoxylin and eosin stained lung sections of vehicle control (ctrl) or ruxolitinib (Ruxo) treated K-rasG12D (K) mice. Right panel: quantitation
of hematoxylin and eosin stained lung sections of ctrl or Ruxo treated K-rasG12D (K) mice. Treatment was started 8 week post tumor initiation,
and continued for 5 weeks (8 + 5wks), with ruxolitinib being administered at 90 mg/kg body weight, seven times per week, BID (scale bars:
400 μm) (n ≥ 9 per group). (b) Graph represents the percentage of tumors with indicated grades in vehicle control and ruxolitinib treated K
mice. (c) Left panel: representative pictures of immunohistochemical stainings for KI67 and cleaved caspase-3 positive cells, comparing
lungs of ctrl or Ruxo treated K mice (8 + 5 weeks). Right panel: quantitation of indicated stainings (scale bars: 50 μm). (d) Results of ﬂow
cytometric analysis depicting the percentage of myeloid cells (left), lymphoid cells (middle) and CD4+ subsets (right) in tumor-harboring lung
lysates of ctrl and Ruxo treated K mice (8 + 5 weeks). (e) Graph displaying relative mRNA expression of the indicated genes normalized to
housekeeping genes (28s, Tbp, Actb) in tumor harboring lungs of ctrl versus Ruxo treated K mice (8 + 5 weeks). (f ) Graph indicating relative
mRNA expression of the indicated genes normalized to housekeeping genes (28s, Tbp, Actb) in tumor harboring lungs of ctrl versus Ruxo
treated K mice (8 + 5 weeks). (g) Left panel: representative pictures of immunohistochemical staining for PD-L1 positive cells of lungs
stemming from ctrl and Ruxo treated K mice (8 + 5 weeks). Right panel: quantitation of indicated staining. (c, g) Mann–Whitney U-test.
Others: Student’s t-test. For all graphs data presented as means  SEM. *p < 0.05, **p < 0.01, ***p < 0.001. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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already established lung ACs. As expected, short-term administra-
tion of ruxolitinib signiﬁcantly diminished activation of JAK–
STAT signaling in the lung lysates of these mice (Fig. 5a and
Fig. S6a). Intriguingly, GSEA analysis also revealed that ruxolitinib
administration signiﬁcantly reduced K-RAS activity in these lungs
(Fig. 5b). Notably, within the top 350 genes negatively regulated
Figure 5. Legend on next page.
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by ruxolitinib (Table S6), we noticed an over-representation of
factors found within GO clusters for chemokine and cytokine
activity (Fig. 5c and Fig. S6b). Accordingly, most of the genes
annotated in these gene sets were downregulated upon ruxolitinib
treatment compared to vehicle control (Fig. 5d and Table S6).
Importantly, 84 of these 109 genes downregulated by ruxolitinib
were either upregulated in K-rasG12D-mutated lung alveolar type
II (K) cells compared to WT cells (67 genes) or in tumor harbor-
ing lungs of KP mice compared to healthy WT lungs (52 genes).
Notably, 35 hits (Tables S2 and S6) were common in all three
groups (Fig. 5e and Figs. S6c and S6d). Among these 35 genes,
key pro-inﬂammatory and pro-tumorigenic factors including ll6,
Tnfα and chemokine (C-X-C motif) ligand 1 (Cxcl1) were found.
The anti-inﬂammatory properties of ruxolitinib were also
observed in the long-term treatment models, as evidenced by
decreased expression of these genes in treated K and KP mice
(Fig. 5f ).
Next, we evaluated the implication of these chemo/cytokines
for human lung AC pathogenesis. Therefore, we took advantage
of a meta-analysis based tool for the assessment of potential bio-
markers in lung AC.25 Multigene classiﬁer analysis revealed that
lower mRNA expression of the signature comprising of 35 genes
was associated with a better survival prognosis in these patients at
a false discover rate < 1% (Fig. S6e and Table S2). Moreover,
lower mRNA levels of lL6, TNFα and IL8, the human orthologue
to mouse Cxcl1 (Fig. 5g), could be associated with a better prog-
nosis in lung AC patients harboring K-RAS mutations.39 Taken
together, we provide here evidence that ruxolitinib treatment
succesfully impairs K-RAS activity in lung tumors and leads to
the establishment of an anti-inﬂammatory and antitumorgenic
tumormicroenviroment.
Discussion
Being a well-deﬁned culprit in myeloproliferative disorders, the
JAK/STAT pathway is a well-known target for pharmaceutical
industry. Ruxolitinib was already Food and Drug Administration
approved in 2011 based on the positive results of the COMFORT-I
clinical trial.40 Somatic mutations rendering JAK2 constitutively
active like the V617F mutation are often found in hematologic
malignancies. However, solid cancers including lung cancer lack
such activating somatic mutations.23,41 Nevertheless, clinical trials
for lungACpatients were launched using JAK inhibitors ruxolitinib,
in particular for patients with activating EGFR-mutations upstream
of JAK1 and JAK2 (NCT02155465, NCT02145637, NCT02917993,
NCT03450330). A recent clinical trial speciﬁcally excluding patients
with EGFR-mutations showed a longer overall survival (5.9 vs.
7.5 months for placebo treated vs. ruxolitinib treated, hazard
ratio = 0.877) when combining ruxolitinib and chemotherapy in
non-small cell lung cancer patients (NCT02119650). However, the
K-RAS mutation status of the involved patients was not disclosed.
Therefore the potential beneﬁt of a JAK1/2 inhibition for K-RAS-
driven lung AC pathogenesis cannot be extrapolated. Hence, as in
other clinical trials when using for example mitogen-activated pro-
tein kinase kinase 1 or rapidly accelerated ﬁbrosarcoma inhibitors, it
would be important for JAK1/2 targeting clinical trials to stratify for
theK-RASmutational status.
Here, we found increased expression of JAKs and activation of
downstream STAT signaling in patients harboring advanced K-
RAS lung AC. Increased JAK levels also correlated with enhanced
K-RAS activity in human lung AC patient samples, suggesting that
JAK/STAT signaling fuels the proliferation of K-RAS-mutated lung
AC. Accordingly, ruxolitinib treatment markedly reduced tumor
cell proliferation of human K-RAS-mutated A549 cells engrafted in
immunodeﬁcient NOD scid gamma mice and reduced a K-RAS
activation gene signature. The engrafted tumors showed decreased
expression of tumor cell-derived, pro-oncogenic cytokines IL-1β
and IL-6, suggesting that ruxolitinib interferes with feed-forward
cytokine signaling which promotes K-RAS tumorigenesis.10 Fur-
thermore, ruxolitinib treatment resulted in tumor growth reduction
in immunocompetent experimental mouse models. Ruxolitinib
impaired K-RAS-driven lung AC not only at early tumor stages but
also in established tumors, independently of the p53 status. Early
treatment of tumors with ruxolitinib resulted in reduced tumor cell
proliferation and reduced apoptosis levels. By contrast, we observed
reduced cell proliferation and increased apoptosis rates in
established tumors upon ruxolitinib treatment. This discrepancy
can be interpreted as the result of a higher cell turnover in early
tumorigenesis or by a tumor-compensatory mechanism upon
Figure 5. JAK inhibition abrogates expression of oncogenic chemokines and cytokines. (a) GSEA of RNA-seq data of lungs of K-rasG12D
(K) mice 8 weeks post tumor induction, treated with vehicle control (ctrl) or ruxolitinib (Ruxo) for four consecutive days before harvesting
(n = 4 per group). The used genesets are HALLMARK_IL6_STAT3_SIGNALING and (b) HALLMARK_KRAS_SIGNALING_UP, comparing ctrl and
Ruxo treatment. (c) Graph depicting the adjusted p-values of enrichment scores of indicated GO-molecular function pathways in ctrl versus
Ruxo treated K mice. The top 350 genes downregulated in lungs of Ruxo treated mice compared to ctrl treated mice were included in the
analysis. (d) Graph shows DESeq calculated log2 fold changes in mRNA expression of indicated up- or downregulated chemokine/cytokine
related genes in tumor bearing lungs of Ruxo treated compared to ctrl treated K mice. (e) Venn diagram depicting amount of overlapping
chemokine and cytokine related genes in all three groups. The deﬁned 35 common genes were found by intersecting the after gene data
sets: genes downregulated in tumor bearing lungs of Ruxo treated mice compared to ctrl treated mice (RUXO-DOWN), genes upregulated in K-
rasG12D mutated alveolar type-II cells compared to WT alveolar type-II cells (KRAS-UP, GSE113146) and genes upregulated in K-ras-
p53-mutated tumor-harboring lungs compared to WT lungs from KP mice (KRAS-P53-UP). (f ) Relative mRNA expression of the indicated genes
normalized to housekeeping genes (28s, Tbp, Actb) in tumor harboring lungs of vehicle control versus ruxolitinib treated KP mice (upper) and
K mice (lower). (g) Graph depicts prognostic value of indicated genes in human K-RAS-mutated lung AC samples. Patients were stratiﬁed
according to auto best cut-off selection. Data were retrieved from the Cancer Genome Atlas (n = 150). Log-rank test was used for statistical
analysis. For (f ) Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. Data presented as means  SEM. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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JAK1/2 inhibition present at early tumor stages. In agreement with
previous reports, ruxolitinib treatment diminished tumor inﬁltrat-
ing CD8+ and CD4+ T cells and signiﬁcantly lowered NK cell num-
bers but did not result in tumor metastasis, even in the absence of
p53.17,18,42 In agreement with others, JAK inhibition abrogated
interferon-γ-mediated STAT1 signaling and reduced PD-L1
expression levels.43 Nevertheless, NK and CD8+ T cell activation
markers were reduced in lungs of ruxolitinib treated mice.
Furthermore, ruxolitinib elevated numbers of tumor inﬁltrating
CD4+IL17A+ Th17 and CD4+Foxp3+ regulatory T cells. Of note,
T cells potentially play a minor role in our experimental mouse
models due to a lack of tumor immunogenicity. In this sense, assess-
ment of JAK inhibitors in T-cell-dependent lung AC experimental
models44 may be a better option and can be more informative to
design and interpret future and ongoing clinical trials, especially
those combining JAK inhibitors and immune checkpoint blockers
(e.g., NCT03425006).
On the other hand, systemic JAK inhibition triggered a slight
reduction of tumor promotingM2macrophages and signiﬁcantly
reduced the abundance of inﬁltrating granulocytic andmonocytic
MDSCs, which is in agreement with an induction of an anti-
tumorigenic TME and the antitumor effects of ruxolitinib.
Importantly, MDSCs andM2 tumor-associated macrophages not
only impede tumor immune surveillance but also support tumor
cell proliferation via cytokine production, and could thereby fos-
ter growth of K-RAS-driven lung AC.38,45 In line with these data,
ruxolitinib treatment of mouse autochthonous lung tumors
mainly affected the expression of pro-tumorigenic chemokines
and cytokines. This chemokine/cytokine milieu is well-known to
be a central modulator of the cancer microenvironment and it
has been established as one of the hallmark drivers of cancer.46
Among these prominently downregulated chemokines and cyto-
kines upon ruxolitinib treatment, we found ll6, Tnfα and Cxcl1.
All of them are well-described pro-inﬂammatory and pro-
tumorigenic chemo- and cytokines. Reduced IL6 levels were
shown to trigger a switch in the TME toward an antitumoral phe-
notype.47 TNFα directly endorses tumor progression and
metastasis.48 Furthermore, CXCL1 has been reported to facilitate
lung cancer cell growth due to the recruitment of MDSCs and
tumor associated neutrophils.13,49 Importantly, all of these factors
were also found to be upregulated in K-rasG12D-mutated lung
alveolar type II (K) cells compared to WT cells or in tumor har-
boring lungs from KP mice compared to non-tumorous lungs
from KP mice. In agreement with this data, low mRNA expres-
sion levels of lL6, Tnfα and IL8 (the human orthologue to murine
Cxcl1) were also associated with a better prognosis in lung AC
patients harboring K-RAS mutations.39 Thus, these data indicate
that lL6, Tnfα and Cxcl1 play a central role for K-RAS driven lung
AC both in human and mice and provides a solid rationality for
using agents blocking inﬂammation-driven tumorigenesis, such
as ruxolitinib, to treat lung AC.7
In summary, we demonstrated here that JAK-mediated signal-
ing is involved in progression of K-RAS-driven lung tumorigene-
sis and that pharmacological inhibition of JAK/STAT signaling
blocks the cytokine-mediated feed-forward loop responsible for
tumor cell proliferation. Additionally, JAK inhibition reprograms
the TME toward an anti-inﬂammatory/antitumorigenic state.
Therefore, our data suggest that ruxolitinib treatment represents
an attractive therapeutic opportunity for treatment of K-RAS-
mutated lung AC.
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